| Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial D Catovsky, S Richards, E Matutes, D Oscier, MJS Dyer, RF Bezares, ... The Lancet 370 (9583), 230-239, 2007 | 936 | 2007 |
| Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis M Else, CE Dearden, E Matutes, J Garcia‐Talavera, AZS Rohatiner, ... British journal of haematology 145 (6), 733-740, 2009 | 302 | 2009 |
| The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial DG Oscier, MJJ Rose-Zerilli, N Winkelmann, D Gonzalez de Castro, ... Blood, The Journal of the American Society of Hematology 121 (3), 468-475, 2013 | 282 | 2013 |
| Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia MR Grever, O Abdel-Wahab, LA Andritsos, V Banerji, J Barrientos, ... Blood, The Journal of the American Society of Hematology 129 (5), 553-560, 2017 | 276 | 2017 |
| Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple … MW Jenner, PE Leone, BA Walker, FM Ross, DC Johnson, D Gonzalez, ... Blood, The Journal of the American Society of Hematology 110 (9), 3291-3300, 2007 | 179 | 2007 |
| The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide … C Dearden, R Wade, M Else, S Richards, D Milligan, T Hamblin, ... Blood, The Journal of the American Society of Hematology 111 (4), 1820-1826, 2008 | 175 | 2008 |
| Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation D Oscier, R Wade, Z Davis, A Morilla, G Best, S Richards, M Else, ... Haematologica 95 (10), 1705, 2010 | 162 | 2010 |
| Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow‐up of 12.5 years M Else, R Ruchlemer, N Osuji, I Del Giudice, E Matutes, A Woodman, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2005 | 139 | 2005 |
| Deletions of CDKN2C in multiple myeloma: biological and clinical implications PE Leone, BA Walker, MW Jenner, L Chiecchio, GP Dagrada, ... Clinical Cancer Research 14 (19), 6033-6041, 2008 | 138 | 2008 |
| Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant G Jones, N Parry‐Jones, B Wilkins, M Else, D Catovsky British journal of haematology 156 (2), 186-195, 2012 | 116 | 2012 |
| Long-term results for pentostatin and cladribine treatment of hairy cell leukemia CE Dearden, M Else, D Catovsky Leukemia & Lymphoma 52 (sup2), 21-24, 2011 | 105 | 2011 |
| The clinical significance of patients’ sex in chronic lymphocytic leukemia D Catovsky, R Wade, M Else Haematologica 99 (6), 1088, 2014 | 103 | 2014 |
| Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route CE Dearden, A Khot, M Else, M Hamblin, E Grand, A Roy, S Hewamana, ... Blood, The Journal of the American Society of Hematology 118 (22), 5799-5802, 2011 | 101 | 2011 |
| Recurrent CDKN1B (p27) mutations in hairy cell leukemia S Dietrich, J Hüllein, SCW Lee, B Hutter, D Gonzalez, S Jayne, MJS Dyer, ... Blood, The Journal of the American Society of Hematology 126 (8), 1005-1008, 2015 | 98 | 2015 |
| Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma M Else, A Marín‐Niebla, F de la Cruz, P Batty, E Ríos, CE Dearden, ... British journal of haematology 159 (3), 322-328, 2012 | 95 | 2012 |
| Stem cell transplantation after alemtuzumab in T‐cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study B Krishnan, M Else, GE Tjonnfjord, B Cazin, D Carney, J Carter, ... British journal of haematology 149 (6), 907-910, 2010 | 89 | 2010 |
| Long-term follow-up after purine analogue therapy in hairy cell leukaemia M Else, CE Dearden, D Catovsky Best Practice & Research Clinical Haematology 28 (4), 217-229, 2015 | 83 | 2015 |
| Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence M Else, CE Dearden, E Matutes, F Forconi, F Lauria, H Ahmad, S Kelly, ... Leukemia & Lymphoma 52 (sup2), 75-78, 2011 | 76 | 2011 |
| The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia M Else, N Osuji, F Forconi, C Dearden, I Del Giudice, E Matutes, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2007 | 73 | 2007 |
| The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma SL Hockley, M Else, A Morilla, A Wotherspoon, C Dearden, D Catovsky, ... British journal of haematology 158 (3), 347-354, 2012 | 69 | 2012 |
Professor Jonathan C StreffordUniversity of SouthamptonVerified email at soton.ac.uk
